| UPADACITINIB | None | ||
| 1MG/1ML |
Less Than $1000 mn
|
||
| None | None | ||
| None | None | ||
| None | None | ||
| RINVOQ/RINVOQ LQ is a Janus kinase (JAK) inhibitor.: • RINVOQ is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more TNF blockers. • RINVOQ/RINVOQ LQ is indicated for the treatment of adults and pediatric patients 2 years of age and older with active psoriatic arthritis who have had an inadequate response or intolerance to one or more TNF blockers. • RINVOQ is indicated for the treatment of adults and pediatric patients 12 years of age and older with refractory, moderate to severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies are inadvisable. • RINVOQ is indicated for the treatment of adults with moderately to severely active ulcerative colitis who have had an inadequate response or intolerance to one or more TNF blockers. • RINVOQ is indicated for the treatment of adults with moderately to se | |||
|
Yes
| |||
| RINVOQ LQ | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 | Patent 11 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| *** ********* | |||||||||||
| ********* ********* | ********* *** *** *********** ** (**,**)-*-*****-*-(**-*******[*,*-*****]*******[*,*-*]-*******-*-**)-*-(*,*,*-**************)***********-*-*********** *** ***** ***** ***** ******* | ********* *** *** *********** ** (**,**)-*-*****-*-(**-*******[*,*-*]*******[*,*-*]-*******-*-**)-*-(*,*,*-**************)***********-*-*********** *** ***** ***** ***** ******* | ********* *** *** *********** ** (**,**)-*-*****-*-(**-*******[*,*-*]*******[*,*-*]-*******-*-**)-*-(*,*,*-**************)***********-*-*********** *** ***** ***** ***** ******* | ********* *** *** *********** ** (**,**)-*-*****-*-(**-*******[*,*-*]*******[*,*-*]-*******-*-**)-*-(*,*,*-**************)***********-*-*********** *** ***** ***** ***** ******* | ********* *** *** *********** ** (**,**)-*-*****-*-(**-*******[*,*-*]*******[*,*-*]-*******-*-**)-*-(*,*,*-**************)***********-*-*********** *** ***** ***** ***** ******* | ********* *** *** *********** ** (**,**)-*-*****-*-(**-*******[*,*-*]*******[*,*-*]-*******-*-**)-*-(*,*,*-**************)***********-*-*********** *** ***** ***** ***** ******* | ********* *** *** *********** ** (**,**)-*-*****-*-(**-*******[*,*-*]*******[*,*-*]- *******-*-**)-*-(*,*,*-**************)***********-*-*********** *** ***** ***** ***** ******* | ********* *** *** *********** ** (**,**)-*-*****-*-(**-*******[*,*-*]*******[*,*-*]-*******-*-**)-*-(*,*,*-**************)***********-*-*********** *** ***** ***** ***** ******* | ********* *** *** *********** ** (**,**)-*-*****-*-(**-*******[*,*-*]*******[*,*-*]-*******-*-**)-*-(*,*,*-**************)***********-*-*********** *** ***** ***** ***** ******* | ********* ********* |
Download ParaIV Report
| Drug Name | Generic Name | Dosage | Route of Administration | Probable FTF | Known Para IV Filers | Other ANDA Developers |
|---|